首页 | 官方网站   微博 | 高级检索  
     

某院肺癌治疗用药分析
引用本文:丰嘉驹,顾嘉钦.某院肺癌治疗用药分析[J].中国药师,2004,7(3):190-193.
作者姓名:丰嘉驹  顾嘉钦
作者单位:上海市胸科医院药剂科,上海,200030
摘    要:目的:分析我院肺癌治疗用药使用状况和发展趋势.方法:以药品消耗金额为量变参数,对我院2000年~2002年肺癌用药的药物消费结构进行调研,同时阐述了这些药物的国内外应用现状及发展趋势.结果:一些较新的药物(吉西他滨、紫杉醇、多西紫杉醇、异长春花碱)在肺癌的一线、二线治疗上显示极具前途的作用,所以这些药物消费金额的增长明显超过肺癌用药消费总金额的增长.结论:新药物的应用将成为肺癌药物治疗的主要趋势.

关 键 词:非小细胞肺癌(NSCLC)  小细胞肺癌(SCLC)  用药分析
文章编号:1008-049X(2004)03-0190-04
修稿时间:2003年7月23日

Analysis of Anticancer Durgs for Pulmonary Carcinoma Used in Shanghai Chest Hospital
Feng jiaju,Gu Jiaqin.Analysis of Anticancer Durgs for Pulmonary Carcinoma Used in Shanghai Chest Hospital[J].China Pharmacist,2004,7(3):190-193.
Authors:Feng jiaju  Gu Jiaqin
Abstract:Objective: To analyse the using situation and developing trend of anticancer drugs for pulmonary carcinoma used in our hospital.Method: Taking sum of drug consumption money as parameter, we investigated the consumption structure of anticancer agents for pulmonary carcinoma in our hospital during 2000 to 2002. And the current situation and developing trend of these anticancer drugs at home and abroad were described.Result: Several `newer' drugs (gemcitabine, paclitaxel, docetaxel and vinorelbine) showed a promising activity in the first-line and second-line therapy of lung cancer, so the increase of sum of money of consumption for these `newer' drugs obviously exceeded that for total drugs. Conclusion: 'Newer' drugs use will be the predominant trend in drug therapy of lung cancer in future.
Keywords:Non-small cell lung cancer (NSCLC)  Small cell lung cancer (SCLC)  Durg-used analysis
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《中国药师》浏览原始摘要信息
点击此处可从《中国药师》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号